Occlugel will be at GEST 2023. ResMic, our degradable microsphere for embolisation will be present on friday 1-2:30 PM Session XI: Masterclass Particles, Resorbables, & Visible.
Occlugel will be at GEST 2023. ResMic, our degradable microsphere for embolisation will be present on friday 1-2:30 PM Session XI: Masterclass Particles, Resorbables, & Visible.
Occlugel is a biotechnology company founded in 2007 by expert clinicians in embolization and chemists specialized in microspheres synthesis and biodegradable polymers.
Occlugel is specialized in innovative implantable medical devices in application fields such as:
Occlugel holds several patents about a novel resorbable biomaterial and its loading with various agents (anticancer drugs, antiangiogenic drugs, anti-inflammatory drugs, growth factors, nucleic acids, pain-killers...)
Occlugel imagine innovative solutions for novel biodegradable and non-degradable polymers.
Occlugel has:
Bédouet, L., Verret, V., Louguet, S., Servais, E., Pascale, F., Beilvert, A., Baylatry, MT., Labarre, D., Moine, L., Laurent, A 2015.Anti-angiogenic drug delivery from hydrophilic resorbable embolization microspheres: an in vitro study with sunitinib and bevacizumab. Int. J. Pharm. 484, 218-227.
Bédouet, L., Pascale, F., Bonneau, M., Laurent, A. 2015. In vitro evaluation of S-(+)-ibuprofen as drug candidate for intra-articular drug delivery system. Drug. Dev. Ind. Pharm. 41, 85-94.
Verret, V., Pelage, J.P., Wassef, M., Louguet, S., Servais, E., Bédouet, L., Beaulieu, T., Moine, L., Laurent, A. 2014. A novel resorbable embolization microsphere for transient uterine arteries occlusion: a comparative study with trisacryl-gelatin microspheres in the sheep model. J. Vasc. Interv. Radiol. 25, 1759-1766.